Results 81 to 90 of about 53,817 (192)
BMC Cancer, 2011 Background This phase 1b study assessed the maximum tolerated dose (MTD), safety, and pharmacokinetics of motesanib (a small-molecule antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) administered once daily (QD)
Sun Yu-Nien +9 more
doaj +1 more source
Glutamine Metabolism in Health and Diseases
MedComm, Volume 7, Issue 10, October 2026.Glutamine metabolism acts as a metabolic hub connecting cellular stress adaptation, immune regulation, and disease development. Through regulating energy production, biosynthesis, redox balance, and nitrogen metabolism, glutamine supports cellular homeostasis under physiological and pathological conditions.
Yi Ding +3 more
wiley +1 more source
, 2014 Yosuke Togashi,1 Hidetoshi Hayashi,1–3 Kazuhiko Nakagawa,2 Kazuto Nishio1 1Department of Genome Biology, 2Department of Medical Oncology, Kindai University Faculty of Medicine, 3Department of Medical Oncology, Kishiwada Municipal Hospital, Osaka ...
Nakagawa K +3 more
core
Erlotinib induced target-like purpura [PDF]
, 2014 Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor, used as a treatment for advanced stage cancer. The most common side effect is cutaneous toxicity including the already known papulopustular reaction.
Rerknimitr, P, Rungtrakulchai, R
core +1 more source
Antioxidant activity of erlotinib and gefitinib: theoretical and experimental insights
, 2022 Erlotinib and gefitinib are quinazoline derivatives with antineoplastic properties. Usually, intake of antineoplastic agents results in much a greater degree of oxidative stress, i.e. the production of free radicals, than induced by cancer itself. Hence,
Pareeth C. M (12509916) +5 more
core +1 more source
Nano Select, Volume 7, Issue 10, October 2026.Surface‐modified niosomes are introduced as multifunctional nanoparticles for precision tumor treatment that combine hydrophilic and lipophilic drug encapsulation with ligand‐based targeting via antibodies, peptides, transferrin, and folic acid. This modification leads to increased tumor selectivity, facilitates cell entry, and enables enhanced ...
Narges Sahraei +3 more
wiley +1 more source
Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
, 2012 Tyrosine kinase inhibitors such as erlotinib are commonly used as a therapeutic agent against cancer due to its relatively low side-effect profile and, at times, greater efficacy.
Wu Reen +3 more
core +1 more source
Acute Fatal Liver Toxicity under Erlotinib [PDF]
, 2010 We describe the case of a never-smoker who received second-line erlotinib as a treatment for his non-small cell lung cancer. Within one month, acute hepatic failure developed as well as a thrombotic-thrombocytopenic microangiopathy, with fatal outcome ...
Schacher-Kaufmann, Sabina +3 more
core +1 more source
Chinese Journal of Lung Cancer, 2009 Background and objective Erlotinib, a selective inhibitor of epidermal growth factor receptor tyrosine kinase, has been approved effective in local advanced or metastatic non-small cell lung cancer (NSCLC).
Baohui HAN +5 more
doaj
Erlotinib‐Induced Pneumatosis Intestinalis: A Case Report and Review of Literature
Respirology Case Reports, Volume 14, Issue 10, October 2026.We report a rare case of erlotinib‐induced pneumatosis intestinalis that worsened during continued treatment and rapidly improved after erlotinib discontinuation. This case highlights the importance of recognizing pneumatosis intestinalis as a potential adverse event of EGFR‐TKIs. ABSTRACT Pneumatosis intestinalis (PI) is a rare condition characterized
Shunsuke Saito +6 more
wiley +1 more source